A Phase 2 interventional study of Pozelimab and Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2021, is one of 3 in phase 2, and was the 4th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Italy and 4 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, Korea, Republic of, United Kingdom
Ages 18+
Regeneron Pharmaceuticals · Sites in Brazil, Canada, Colombia and 18 more countries
Ages 18+
By country, each count listing its studies:
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5
First in 2019; this study’s year is marked. 2 started in 2021.
This study's enrollment of 6 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 24 across the 9 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the safety and tolerability of pozelimab and cemdisiran combination therapy in participants with PNH who switch from eculizumab therapy
The secondary objectives of the study are:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pozelimab · Drug: Cemdisiran
Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
Also known as: REGN3918
SC administration
Also known as: ALN-CC5
OLTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to Day 225
OLTP: Percent Change in Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period
Time frame: Screening (Day 1) through Day 225
OLTP: Percent Change in LDH From Pre-treatment Through Day 29
Time frame: Screening (Day 1) through Day 29
OLTP: Percentage of Participants Who Were Transfusion-free From Baseline Through Week 32
Time frame: Baseline through Week 32
OLTP: Percentage of Participants Who Were Transfusion-free From Week 4 Through Week 32
Time frame: Week 4 through Week 32
OLTP: Rate of Red Blood Cell (RBC) Transfusions From Baseline Through Week 32
The rate of units of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.
Time frame: Baseline through Week 32
OLTP: Rate of RBC Transfusions From Week 4 Through Week 32
The rate of units of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.
Time frame: Week 4 through Week 32
OLTP: Number of RBC Units Transfused From Baseline Through Week 32
Time frame: Baseline through Week 32
OLTP: Number of RBC Units Transfused From Week 4 Through Week 32
Time frame: Week 4 through Week 32
OLTP: Percentage of Participants With Breakthrough Hemolysis From Baseline Through Week 32
Breakthrough hemolysis was defined as having an LDH ≥ 2 x upper limit of normal (ULN) and having signs or symptoms.
Time frame: Baseline through Week 32
OLTP: Percentage of Participants With Breakthrough Hemolysis From Week 4 Through Week 32
Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.
Time frame: Week 4 through Week 32
OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 32
Adequate control was defined as LDH ≤ 1.5 x ULN from Day 1 through Week 32.
Time frame: Day 1 through Week 32
OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Week 8 Through Week 32
Adequate control was defined as LDH ≤ 1.5 x ULN from Week 8 through Week 32.
Time frame: Week 8 through Week 32
OLTP: Number of Participants With Adequate Control of Hemolysis at Each Visit
Adequate control at a visit was defined as having LDH ≤1.5 x ULN at that visit.
Time frame: Days 1, 8, 15, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225
OLTP: Number of Participants With Normalization of Their LDH at Each Visit
Normalization was defined as LDH ≤ 1.0 x ULN at that visit.
Time frame: Days 1, 8, 15, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225
OLTP: Average LDH From Baseline Through Week 32
The trapezoidal rule was used to calculate area under the curve (AUC). Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.
Time frame: Baseline through Week 32
OLTP: Average LDH From Week 8 Through Week 32
The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.
Time frame: Week 8 through Week 32
OLTP: Percentage of Participants With Hemoglobin Stabilization From Baseline Through Week 32
Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 grams per deciliter (g/dL).
Time frame: Baseline through Week 32
OLTP: Percentage of Participants With Hemoglobin Stabilization From Week 4 Through Week 32
Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.
Time frame: Week 4 through Week 32
OLTP: Change From Baseline in Hemoglobin Levels
Time frame: Baseline, Week 32
OLTP: Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score
The FACIT-Fatigue is a 13-item, self-reported measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in participants with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Total scores range from 0 to 52, with higher scores indicating a higher quality of life.
Time frame: Baseline, Week 32
OLTP: Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by the Global Health Status Subscale of the European Organization for Research and Treatment of Cancer (EORTC)- Quality of Life Cancer Patients Questionnaire (QLQ) - 30 Scale
EORTC-QLQ-C30 is a 30-item self-reported questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. The GHS subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.
Time frame: Baseline, Week 32
OLTP: Change From Baseline in Physical Function (PF) Scores on the EORTC QLQ-C30
EORTC-QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a PF scale. PF subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.
Time frame: Baseline, Week 32
OLTP: Change From Baseline in Total Complement Hemolytic Activity Assay (CH50)
This assay assessed the activity of the classical pathway of complement to measure C5 activity.
Time frame: Baseline through Week 32
OLTP and OLEP: Concentration of Total Pozelimab in Serum
Time frame: Pre-dose Days 28, 56, 84, 112, 140, 168, 196, 224, 392, 588; Post-dose Day 28
OLTP: Concentration of Total Eculizumab in Serum
Time frame: Pre-dose Days 0, 14, 28, 56, 84, 112, 140, 168, 196, 224
OLTP and OLEP: Concentration of Total Cemdisiran in Plasma
Time frame: Pre-dose and Post-dose Days 0, 84, 196, 224, 588
OLTP and OLEP: Concentration of Total C5 in Plasma
Time frame: Pre-dose Days 0, 7, 14, 28, 56, 84, 112, 140, 168, 196, 224, 392, 588
OLTP: Number of Participants With Pozelimab Anti-drug Antibodies (ADA)
Time frame: Baseline through Week 32
OLTP: Number of Participants With Cemdisiran ADA
Time frame: Baseline through Week 32
OLTP: Number of Participants Who Received Dose Intensification With TEAEs
Time frame: Baseline through Week 32
OLEP: Number of Participants With TEAEs
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Percent Change in LDH From Day 1 Through Week 24 of the OLEP
Time frame: Day 1 through Week 24 of the OLEP
OLEP: Percent Change in LDH From Day 1 Through Week 52 of the OLEP
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 24 of the OLEP
Time frame: Day 1 through Week 24 of the OLEP
OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 52 of the OLEP
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Rate of RBC Transfusions From Day 1 Through Week 24 of the OLEP
The rate of units of transfusion for a participants was calculated based on the duration of treatment exposure of the participant.
Time frame: Day 1 through Week 24 of the OLEP
OLEP: Rate of RBC Transfusions From Day 1 Through Week 52 of the OLEP
The rate of units of transfusion for a participants was calculated based on the duration of treatment exposure of the participant.
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Number of RBC Units Transfused From Day 1 Through Week 24 of the OLEP
Time frame: Day 1 through Week 24 of the OLEP
OLEP: Number of RBC Units Transfused From Day 1 Through Week 52 of the OLEP
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 24 of the OLEP
Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.
Time frame: Day 1 through Week 24 of the OLEP
OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 52 of the OLEP
Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 24 of the OLEP
Adequate control was defined as LDH ≤ 1.5 x ULN.
Time frame: Day 1 through Week 24 of the OLEP
OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 52 of the OLEP
Adequate control was defined as LDH ≤ 1.5 x ULN.
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Number of Participants Who Maintained Adequate Control of Hemolysis at Each Visit in OLEP
Adequate control was defined as LDH ≤ 1.5 x ULN at that visit.
Time frame: Baseline, Days 57, 113, 169, 225, 281, 365 of the OLEP
OLEP: Number of Participants With Normalization of Their LDH at Each Visit in OLEP
Normalization was defined as LDH ≤ 1.0 x ULN at that visit.
Time frame: Baseline, Days 57, 113, 169, 225, 281, 365 of the OLEP
OLEP: Average LDH From Day 1 Through Week 24 of the OLEP
The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.
Time frame: Day 1 through Week 24 of the OLEP
OLEP: Average LDH From Day 1 Through Week 52 of the OLEP
The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 24 of the OLEP
Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.
Time frame: Day 1 through Week 24 of the OLEP
OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 52 of the OLEP
Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Change From Baseline in Hemoglobin Levels
Time frame: Day 1 and Week 24 of the OLEP
OLEP: Change From Baseline in Hemoglobin Levels
Time frame: Day 1 and Week 52 of the OLEP
OLEP: Change From Baseline in FACIT-Fatigue Score
The FACIT-Fatigue is a 13-item, self-reported measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Total scores range from 0 to 52, with higher scores indicating a higher quality of life.
Time frame: Day 1 and Week 52 of the OLEP
OLEP: Change From Baseline in HRQoL as Measured by the Global Health Status Subscale of the EORTC-QLQ-30 Scale
EORTC-QLQ-C30 is a 30-item self-reported questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. GHS subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.
Time frame: Day 1 and Week 52 of the OLEP
OLEP: Change From Baseline in PF Scores on the EORTC QLQ-C30
EORTC-QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a PF scale. PF subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.
Time frame: Day 1 and Week 52 of the OLEP
OLEP: Change From Baseline in CH50
This assay assessed the activity of the classical pathway of complement to measure C5 activity.
Time frame: Baseline, Week 16, Week 32, Week 52 of the OLEP
OLEP: Number of Participants With Pozelimab ADA
Time frame: Day 1 through Week 52 of the OLEP
OLEP: Number of Participants With Cemdisiran ADA
Time frame: Day 1 through Week 52 of the OLEP
| Milestone | Participants With PNH |
|---|---|
| Started | 6 |
| Completed | 5 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | Participants With PNH |
|---|---|
| Started | 5 |
| Completed | 5 |
| Not completed | 0 |
| Participants | Participants With PNH |
|---|---|
| OLTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 6 |
| percent change | Participants With PNH |
|---|---|
| OLTP: Percent Change in Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period | -0.95 ± 13.40 |
| percent change | Participants With PNH |
|---|---|
| OLTP: Percent Change in LDH From Pre-treatment Through Day 29 | 3.61 ± 35.99 |
| percentage of participants | Participants With PNH |
|---|---|
| OLTP: Percentage of Participants Who Were Transfusion-free From Baseline Through Week 32 | 100 (100.0 to 100.0) |
| percentage of participants | Participants With PNH |
|---|---|
| OLTP: Percentage of Participants Who Were Transfusion-free From Week 4 Through Week 32 | 100 (100.0 to 100.0) |
The rate of units of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.
| transfusions per person-year | Participants With PNH |
|---|---|
| OLTP: Rate of Red Blood Cell (RBC) Transfusions From Baseline Through Week 32 | 0 (NA to NA) |
The rate of units of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.
| transfusions per person-year | Participants With PNH |
|---|---|
| OLTP: Rate of RBC Transfusions From Week 4 Through Week 32 | 0 (NA to NA) |
| RBC units | Participants With PNH |
|---|---|
| OLTP: Number of RBC Units Transfused From Baseline Through Week 32 | 0 ± 0.0 |
| RBC units | Participants With PNH |
|---|---|
| OLTP: Number of RBC Units Transfused From Week 4 Through Week 32 | 0 ± 0.0 |
Breakthrough hemolysis was defined as having an LDH ≥ 2 x upper limit of normal (ULN) and having signs or symptoms.
| percentage of participants | Participants With PNH |
|---|---|
| OLTP: Percentage of Participants With Breakthrough Hemolysis From Baseline Through Week 32 | 0.0 (0.0 to 0.0) |
Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.
| percentage of participants | Participants With PNH |
|---|---|
| OLTP: Percentage of Participants With Breakthrough Hemolysis From Week 4 Through Week 32 | 0.0 (0.0 to 0.0) |
Adequate control was defined as LDH ≤ 1.5 x ULN from Day 1 through Week 32.
| percentage of participants | Participants With PNH |
|---|---|
| OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 32 | 83.3 (53.5 to 100.0) |
Adequate control was defined as LDH ≤ 1.5 x ULN from Week 8 through Week 32.
| percentage of participants | Participants With PNH |
|---|---|
| OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Week 8 Through Week 32 | 83.3 (53.5 to 100.0) |
Adequate control at a visit was defined as having LDH ≤1.5 x ULN at that visit.
| Participants | Participants With PNH |
|---|---|
| Day 1 | 6 |
| Day 8 | 5 |
| Day 15 | 5 |
| Day 29 | 6 |
| Day 43 | 5 |
| Day 57 | 5 |
| Day 71 | 5 |
| Day 85 | 5 |
| Day 113 | 4 |
| Day 141 | 5 |
| Day 169 | 4 |
| Day 197 | 3 |
| Day 225 | 5 |
Normalization was defined as LDH ≤ 1.0 x ULN at that visit.
| Participants | Participants With PNH |
|---|---|
| Day 1 | 6 |
| Day 8 | 5 |
| Day 15 | 5 |
| Day 29 | 6 |
| Day 43 | 5 |
| Day 57 | 4 |
| Day 71 | 5 |
| Day 85 | 4 |
| Day 113 | 4 |
| Day 141 | 5 |
| Day 169 | 4 |
| Day 197 | 3 |
| Day 225 | 5 |
The trapezoidal rule was used to calculate area under the curve (AUC). Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.
| Units per Liter (U/L) | Participants With PNH |
|---|---|
| OLTP: Average LDH From Baseline Through Week 32 | 227.34 ± 45.08 |
The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.
| U/L | Participants With PNH |
|---|---|
| OLTP: Average LDH From Week 8 Through Week 32 | 223.49 ± 49.01 |
Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 grams per deciliter (g/dL).
| percentage of participants | Participants With PNH |
|---|---|
| OLTP: Percentage of Participants With Hemoglobin Stabilization From Baseline Through Week 32 | 100 (100.0 to 100.0) |
Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.
| percentage of participants | Participants With PNH |
|---|---|
| OLTP: Percentage of Participants With Hemoglobin Stabilization From Week 4 Through Week 32 | 100 (100.0 to 100.0) |
| g/dL | Participants With PNH |
|---|---|
| OLTP: Change From Baseline in Hemoglobin Levels | 0.54 ± 0.60 |
The FACIT-Fatigue is a 13-item, self-reported measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in participants with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Total scores range from 0 to 52, with higher scores indicating a higher quality of life.
| score on a scale | Participants With PNH |
|---|---|
| OLTP: Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score | -1.0 |
EORTC-QLQ-C30 is a 30-item self-reported questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. The GHS subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.
| score on a scale | Participants With PNH |
|---|---|
| OLTP: Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by the Global Health Status Subscale of the European Organization for Research and Treatment of Cancer (EORTC)- Quality of Life Cancer Patients Questionnaire (QLQ) - 30 Scale | -8.333 |
EORTC-QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a PF scale. PF subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.
| score on a scale | Participants With PNH |
|---|---|
| OLTP: Change From Baseline in Physical Function (PF) Scores on the EORTC QLQ-C30 | 6.667 |
This assay assessed the activity of the classical pathway of complement to measure C5 activity.
| International units per mL (IU/mL) | Participants With PNH |
|---|---|
| OLTP: Change From Baseline in Total Complement Hemolytic Activity Assay (CH50) | 0.0 ± 0.0 |
| milligrams per liter (mg/L) | Participants With PNH |
|---|---|
| Pre-dose Day 28 | 0 ± 0 |
| 15 Minutes Post-dose Day 28 | 1280 ± 193 |
| Pre-dose Day 56 | 333 ± 48.1 |
| Pre-dose Day 84 | 189 ± 54.8 |
| Pre-dose Day 112 | 121 ± 57.2 |
| Pre-dose Day 140 | 102 ± 40.7 |
| Pre-dose Day 168 | 70.1 ± 37.3 |
| Pre-dose Day 196 | 86.1 ± 36.6 |
| Pre-dose Day 224 | 71.7 ± 41.4 |
| Pre-dose Day 392 | 53.1 ± 25.6 |
| Pre-dose Day 588 | 51.1 ± 25.6 |
| mg/L | Participants With PNH |
|---|---|
| Pre-dose Day 0 | 231 ± 64.5 |
| Pre-dose Day 14 | 225 ± 63.2 |
| Pre-dose Day 28 | 242 ± 59.0 |
| Pre-dose Day 56 | 101 ± 42.9 |
| Pre-dose Day 84 | 44.4 ± 38.7 |
| Pre-dose Day 112 | 22.5 ± 29.5 |
| Pre-dose Day 140 | 12.6 ± 12.5 |
| Pre-dose Day 168 | 4.23 ± 6.46 |
| Pre-dose Day 224 | 0.540 ± 1.16 |
| nanograms per milliliter (ng/mL) | Participants With PNH |
|---|---|
| Pre-dose Day 0 | 0 ± 0 |
| Post-dose Day 0 | 139 ± 45.5 |
| Pre-dose Day 84 | 0 ± 0 |
| Post-dose Day 84 | 178 ± 111 |
| Pre-dose Day 196 | 0 ± 0 |
| Post-dose Day 196 | 196 ± 100 |
| Pre-dose Day 224 | 0 ± 0 |
| Post-dose Day 224 | 158 ± 75.7 |
| Pre-dose Day 588 | 0 ± 0 |
| Post-dose Day 588 | 215 ± 84.8 |
| mg/L | Participants With PNH |
|---|---|
| Pre-dose Day 0 | 320 ± 64.2 |
| Pre-Dose Day 7 | 191 ± 46.2 |
| Pre-dose Day 14 | 118 ± 28.0 |
| Pre-dose Day 28 | 54.5 ± 14.2 |
| Pre-dose Day 56 | 2.77 ± 6.78 |
| Pre-dose Day 84 | 2.90 ± 6.48 |
| Pre-dose Day 112 | 3.88 ± 7.75 |
| Pre-dose Day 140 | 3.10 ± 6.93 |
| Pre-dose Day 168 | 4.79 ± 7.18 |
| Pre-dose Day 196 | 2.03 ± 4.05 |
| Pre-dose Day 224 | 4.96 ± 7.44 |
| Pre-dose Day 392 | 5.02 ± 7.13 |
| Pre-dose Day 588 | 5.28 ± 7.44 |
| Participants | Participants With PNH |
|---|---|
| OLTP: Number of Participants With Pozelimab Anti-drug Antibodies (ADA) | 0 |
| Participants | Participants With PNH |
|---|---|
| OLTP: Number of Participants With Cemdisiran ADA | 0 |
No measurements were reported for this outcome.
| Participants | Participants With PNH |
|---|---|
| OLEP: Number of Participants With TEAEs | 5 |
| percent change | Participants With PNH |
|---|---|
| OLEP: Percent Change in LDH From Day 1 Through Week 24 of the OLEP | -6.17 ± 9.15 |
| percent change | Participants With PNH |
|---|---|
| OLEP: Percent Change in LDH From Day 1 Through Week 52 of the OLEP | -3.46 ± 10.94 |
| percentage of participants | Participants With PNH |
|---|---|
| OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 24 of the OLEP | 100 (100.0 to 100.0) |
| percentage of participants | Participants With PNH |
|---|---|
| OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 52 of the OLEP | 80.0 (44.9 to 100.0) |
The rate of units of transfusion for a participants was calculated based on the duration of treatment exposure of the participant.
| transfusions per person-year | Participants With PNH |
|---|---|
| OLEP: Rate of RBC Transfusions From Day 1 Through Week 24 of the OLEP | 0 (NA to NA) |
The rate of units of transfusion for a participants was calculated based on the duration of treatment exposure of the participant.
| transfusions per person-year | Participants With PNH |
|---|---|
| OLEP: Rate of RBC Transfusions From Day 1 Through Week 52 of the OLEP | 0.200 (0.028 to 1.421) |
| RBC units | Participants With PNH |
|---|---|
| OLEP: Number of RBC Units Transfused From Day 1 Through Week 24 of the OLEP | 0 ± 0.0 |
| RBC units | Participants With PNH |
|---|---|
| OLEP: Number of RBC Units Transfused From Day 1 Through Week 52 of the OLEP | 0.4 ± 0.9 |
Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.
| percentage of participants | Participants With PNH |
|---|---|
| OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 24 of the OLEP | 0.0 (0.0 to 0.0) |
Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.
| percentage of participants | Participants With PNH |
|---|---|
| OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 52 of the OLEP | 0.0 (0.0 to 0.0) |
Adequate control was defined as LDH ≤ 1.5 x ULN.
| percentage of participants | Participants With PNH |
|---|---|
| OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 24 of the OLEP | 100 (100.0 to 100.0) |
Adequate control was defined as LDH ≤ 1.5 x ULN.
| percentage of participants | Participants With PNH |
|---|---|
| OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 52 of the OLEP | 100 (100.0 to 100.0) |
Adequate control was defined as LDH ≤ 1.5 x ULN at that visit.
| Participants | Participants With PNH |
|---|---|
| Baseline OLEP | 5 |
| Day 57 OLEP | 5 |
| Day 113 OLEP | 5 |
| Day 169 OLEP | 5 |
| Day 225 OLEP | 5 |
| Day 281 OLEP | 5 |
| Day 365 OLEP | 5 |
Normalization was defined as LDH ≤ 1.0 x ULN at that visit.
| Participants | Participants With PNH |
|---|---|
| Baseline OLEP | 5 |
| Day 57 OLEP | 5 |
| Day 113 OLEP | 5 |
| Day 169 OLEP | 5 |
| Day 225 OLEP | 5 |
| Day 281 OLEP | 5 |
| Day 365 OLEP | 4 |
The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.
| U/L | Participants With PNH |
|---|---|
| OLEP: Average LDH From Day 1 Through Week 24 of the OLEP | 210.55 ± 42.64 |
The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.
| U/L | Participants With PNH |
|---|---|
| OLEP: Average LDH From Day 1 Through Week 52 of the OLEP | 210.13 ± 44.91 |
Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.
| percentage of participants | Participants With PNH |
|---|---|
| OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 24 of the OLEP | 100 (100.0 to 100.0) |
Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.
| percentage of participants | Participants With PNH |
|---|---|
| OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 52 of the OLEP | 80.0 (44.9 to 100.0) |
| g/dL | Participants With PNH |
|---|---|
| OLEP: Change From Baseline in Hemoglobin Levels | -0.10 ± 0.52 |
| g/dL | Participants With PNH |
|---|---|
| OLEP: Change From Baseline in Hemoglobin Levels | 0.16 ± 0.70 |
The FACIT-Fatigue is a 13-item, self-reported measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Total scores range from 0 to 52, with higher scores indicating a higher quality of life.
| score on a scale | Participants With PNH |
|---|---|
| OLEP: Change From Baseline in FACIT-Fatigue Score | -2.4 ± 8.7 |
EORTC-QLQ-C30 is a 30-item self-reported questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. GHS subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.
| score on a scale | Participants With PNH |
|---|---|
| OLEP: Change From Baseline in HRQoL as Measured by the Global Health Status Subscale of the EORTC-QLQ-30 Scale | -10.000 ± 18.066 |
EORTC-QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a PF scale. PF subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.
| score on a scale | Participants With PNH |
|---|---|
| OLEP: Change From Baseline in PF Scores on the EORTC QLQ-C30 | 0.000 ± 4.714 |
This assay assessed the activity of the classical pathway of complement to measure C5 activity.
| IU/mL | Participants With PNH |
|---|---|
| Change at Week 16 | 0.0 ± 0.0 |
| Change at Week 32 | 0.6 ± 1.3 |
| Change at Week 52 | 1.2 ± 1.8 |
| Participants | Participants With PNH |
|---|---|
| OLEP: Number of Participants With Pozelimab ADA | 0 |
| Participants | Participants With PNH |
|---|---|
| OLEP: Number of Participants With Cemdisiran ADA | 0 |
Collected over From signing informed consent up to 84 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OLTP: Participants With PNH | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| OLEP: Participants With PNH | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Event | OLTP: Participants With PNH | OLEP: Participants With PNH |
|---|---|---|
| HaemolysisBlood and lymphatic system disorders | 0/6 | 1/5 |
| Respiratory tract infectionInfections and infestations | 0/6 | 1/5 |
| Endometrial hyperplasiaReproductive system and breast disorders | 1/6 | 0/5 |
| Event | OLTP: Participants With PNH | OLEP: Participants With PNH |
|---|---|---|
| Injection site reactionGeneral disorders | 5/6 | 3/5 |
| HeadacheNervous system disorders | 3/6 | 1/5 |
| COVID-19Infections and infestations | 2/6 | 2/5 |
| NasopharyngitisInfections and infestations | 1/6 | 2/5 |
| HypertensionVascular disorders | 0/6 | 2/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/6 | 0/5 |
| Viral upper respiratory tract infectionInfections and infestations | 1/6 | 1/5 |
| Lower respiratory tract infectionInfections and infestations | 0/6 | 1/5 |
| Respiratory tract infectionInfections and infestations | 0/6 | 1/5 |
| SinusitisInfections and infestations | 0/6 | 1/5 |
The safety analysis set included all participants who received any amount of study drug.
| Age, Continuous(years) | Participants With PNH |
|---|---|
| Mean | 51.3 ± 11.7 |
| Sex: Female, Male(Participants) | Participants With PNH |
|---|---|
| Female | 3 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Participants With PNH |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Participants With PNH |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Jul 2021 to primary completion in May 2022, 9 months.
Results were first posted in Jun 2025, 3 years 1 month after primary completion. A results delay was requested in May 2023.
Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 9 months is below that.
Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pozelimab · Cemdisiran